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Dopamine receptors
opamine receptors are divided into two families,
D1-like and D2-like receptors.Both families are of G-pro-
tein coupled receptors (GPCRs). Didactically, D1-like
(D1 and D5) are coupled to Gs and D2-like (D2,D 3 and
D4) are coupled to Gi.However,this is a simplified way
of looking at the functions of the dopamine receptors.
Recent evidence shows that these receptors do not work
only via Gi or Gs,nor is their activation via ligand bind-
ing the same in every cell.
1
Receptor-receptor interaction
G-protein coupled receptors are able to form dimers
within arrays of oligomers.
2 Both homo- and hetero-
oligomers were found for almost all kinds of GPCRs stud-
ied.Most interesting was the finding that the heteromeric
receptors shown functions different from the individual
and homo-oligomers, and dopamine receptors are no
exception.It has been reported that D1 and D2 receptors
associate within neurons,and that association results in a
phospholipase C (PLC)-mediated increase in intracellular
calcium,which is a pathway that is not activated by either
receptor alone.
3-5These findings gain relevance consider-
ing that abnormal calcium signaling seems to have a poten-
tially important role in schizophrenia
6,7 and that the effi-
cacy of antipsychotic drugs is closely related to their effect
on dopamine receptors. D2 and D3 dopamine receptors
also form heteromeric complexes with other neurotrans-
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Changes in dopaminergic function can be regulated by
receptor-receptor interaction, or interaction with other
proteins with dopamine receptors, and/or elements of
the downstream signaling cascades. The complexity of
dopaminergic signaling is far from being completely elu-
cidated. It could, however, hold the key to the compre-
hension of the pathophysiology of neurological and psy-
chiatric disorders, as well as to the identification of
putative new targets for, and development of, more effi-
cacious and selective drugs. Here, we review some of the
current evidence and new ideas that are being proposed
as a result, as well as future perspectives that are now
being recognized.      
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8-10 which will
encourage the development of adenosine and dopamine
antagonist/agonist compounds with selective effect on het-
eromers as potential drugs in treatment of schizophrenia
and other neuropsychiatric disorders.
DARPP-32
Recently, Albert et al
11 reported that DARPP-32
(dopamine- and cyclic AMP-regulated phosphoprotein,of
relative molecular mass 32 000) was significantly reduced
in the dorsolateral prefrontal cortex in more schizophrenic
subjects when compared with paired controls,while the
levels of other synaptic phosphoproteins,synapsin I and
the calcium/calmodulin-dependent protein kinase II,did
not differ between schizophrenics and controls.This was
not due to medication,since subjects with Alzheimer's dis-
ease,treated or untreated with neuroleptic agents,did not
show a decrease in DARPP-32 levels.Their finding was
consistent with a selective reduction in DARPP-32 levels
in schizophrenic subjects, which may be involved in the
known prefrontal dysfunction associated with the disease.
DARPP-32's inhibitory effect on protein phosphatase 1
(PP1) is activated when it is phosphorylated by protein
kinase A (PKA) on threonine 34,and is terminated by the
action of protein phosphatase 2B (PP-2B),which is in turn
activated by calcium from intracellular stores,which can
be mobilized by activation of D2 receptors.Hernandez-
Lopez et al
12 reported that D2 suppresses transmembrane
calcium (Ca
2+) currents through L-type Ca
2+ channels
mediated by Gβγ activation of phospholipase Cβ1,mobi-
lization of intracellular Ca
2+ stores,and activation of the
calcium-dependent phosphatase calcineurin.
Neuronal calcium sensor-1
Koh et al
13 demonstrated, also in the dorsolateral pre-
frontal cortex,that samples from schizophrenic and bipo-
lar subjects display significantly elevated levels of neu-
ronal calcium sensor-1 (NCS-1), which were not influ-
enced by age,gender,hemisphere,cause of death,post-
mortem period, alcohol consumption, or use of
psychotropic medication.These data were reproduced
and expanded with the finding that another calcium sen-
sor,calcyon,was also upregulated in the brains of schiz-
ophrenic patients compared with controls.
14,15 In striatum,
NCS-1 and the D2 dopamine receptor (DRD2) were
found to colocalize within sites of synaptic transmission
and in close proximity to intracellular calcium stores.
16
Those authors proposed that NCS-1-D2 receptor inter-
action may serve to couple dopamine and calcium sig-
naling pathways,thus providing a component in the reg-
ulation of dopaminergic signaling which might be
involved in brain diseases.
It has been a long-standing pursuit of biological psychi-
atry to define dopaminergic dysfunction in psychiatric
patients,and the search for mechanisms downstream of
membrane receptors has begun.In this particular case it
is interesting to notice that both proteins are involved in
dopaminergic signaling.DARPP-32 is phosphorylated by
PKA activated via D1 dopamine receptors which are
coupled to Gs.
17 On the other hand,NCS-1 was shown to
be able to mediate desensitization of D2 dopamine recep-
tors,attenuating agonist-induced receptor internalization
via a mechanism that involves a reduction in D2 receptor
phosphorylation,which was accompanied by an increase
in D2 receptor-mediated cyclic adenosine monophos-
phate (cAMP) inhibition after dopamine stimulation.
16
This was recently confirmed by ultrastructural micro-
scopic techniques.
18Thus,DARPP-32 and NCS-1 seem to
be participants in two opposing dopaminergic pathways,
one linked to the D1-Gs-coupled receptors and the other
to D2-Gi-coupled receptors.
PC12 cells are commonly used as a neuronal model,
given that they exhibit properties such as excitability,
secretion, and expression of metabotropic and
ionotropic receptors of different types, including
dopamine receptors. In addition, PC12 cultures can be
differentiated to develop extensive neurites resembling
neuronal dendritic trees by using nerve growth factor
(NGF).Thus,in order to further investigate the possible
interrelations between NCS-1 and DARPP-32 pathways
we used PC12 cells of wild type (WT) and a lineage
(clone 2) stably overexpressing NCS-1.Our data showed
that the amount of DARPP-32 in c2 cells was at least 3
times smaller than in the WT PC12 cells, which was in
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Selected abbreviations and acronyms
AKT-1 V-akt murine thymoma viral oncogene homolog-1
DARPP-32 dopamine- and cyclic AMP-regulated 
phosphoprotein-32
GSK glycogen synthase kinase
NCS-1 neuronal calcium sensor-1
PAR-4 prostate apoptosis response-4
PK protein kinase
RGS Regulator of G protein signalingagreement with the above described results obtained
from prefrontal cortex of schizophrenic patients (Souza
et al,unpublished data).
PAR-4 and calmodulin
Prostate apoptosis response 4 (PAR-4) is a leucine zip-
per containing protein that plays a role in apoptosis.
Recently,it was reported that PAR-4 binds to the third
intracellular loop of the D2 receptor.
19The PAR-4 bind-
ing site to D2 is in the same region where calmodulin
(CaM)binds to the receptor.In increased Ca
2+ concen-
trations,calmodulin competes with PAR-4,decreasing its
binding.
CaM is a small acidic protein that functions as a primary
decoder of Ca
2+ information in the cell. CaM acts as a
switch when the Ca
2+ concentration rises from resting.
20
CaM regulates several enzymes that are of interest for
synaptic plasticity including adenylyl cyclases, protein
kinases and phosphatases,nitric oxide synthase,and Ca
2+
channels.
21 Among them is calcineurin, also known as
PP2B.
Calmodulin is also a modulator of G protein signaling-4
(RGS4),a protein codified by a gene that was shown to
have modest but significant association between poly-
morphisms and haplotypes in RGS4 and schizophrenia
22-
25; however, there have also been negative reports.
26,27
Using microarray technology Mirnics et al
28 found a
decrease in RGS4 messenger ribonucleic acid (mRNA)
in the prefrontal cortex of schizophrenic patients.The
RGS4 gene is located at chromosome 1q23.3 within a
known susceptibility locus for schizophrenia.
29 During the
resting state RGS binds to phosphatidylinositol 3,4,5-
trisphosphate (PIP3) inhibiting its action.During depo-
larization,Ca
2+ enters the cells and binds to CaM,form-
ing a complex that is able to recover RGS function by
removing PIP3 inhibition.
30-34 It was found that there was
a reciprocal control of RGS4 by PIP3 and CaM,and that
CaM and PIP3 share the same binding site intercating
competitively to controls RGS4 function.
35 Knockout
mice for RGS4 did not present a decrease in prepulse
inhibition (PPI) or any other behavioral alteration except
for a subtle and complex sensorimotor deficit.
36
Gene expression changes of RGS4 were observed with
specific dopamine receptor agents,such as an increase in
RGS4 by D2 receptor stimulation or by D1 receptor
blockade.
37,38 It was found that spinophilin also binds to
RGS4.
39 Using yeast two hybrid assays, Jeanneteau et
al
40,41 identified an interaction between G alpha-interact-
ing protein (GAIP-interacting protein), C terminus
(GIPC) and D2 and D3, but not with D4.They showed
that when GIPC was recruited by dopamine receptors,
their signaling function was reduced by increased seques-
tration into vesicles;however,at the same time they were
protected from degradation.GIPC interacts specifically
with another RGS protein,GAIP,which exerts GTPase
function through direct interactions on activated (GTP-
bound) form of G proteins to limit their lifetime and ter-
minate signaling.
Park et al
19 have shown a correlation of PAR-4 with
depressive symptoms in animal models.Although no data
was reported in relation to schizophrenia,the regulation of
D2 activity by PAR-4 might show relevance in near future.
Actin-binding proteins
Spinophilin 
Spinophilin was first described in 1997 as a novel F-actin
and protein phosphatase-1 binding protein localized to
dendritic spines.
42 It possesses a single PDZ domain,and
was identified as a protein that specifically associates with
the third cytoplasmic loop of the D2 receptors.
43The bind-
ing site with D2 is distinct from that for PP1,meaning that
spinophilin can bind both at the same time.
It was also recently reported that spinophilin antagonizes
arrestin-stabilized receptor phosphorylation through
blocking G-protein receptor kinase 2 (GRK2) association
with receptor-G β−γ complexes,reducing receptor endo-
cytosis.
39This effect is similar to that reported for NCS-1.
16
Spinophilin was implicated in schizophrenia by a study
showing that its expression levels were reduced in hip-
pocampus of schizophrenic patients;however,the changes
were not specific for schizophrenia,being similar to those
found in mood disorder patients.
44 However,Clinton et al
45
showed contradictory data where spinophilin transcripts
was increased in brains of schizophrenic patients,along
with confirmation of increased levels of calcyon.
ABP-280; filamin A 
Another actin-binding protein-280 (ABP-280) or filamin
A is a abundant cytoplasmic protein that has an actin-
binding domain at its N terminus. It was shown that
ABP-280 can interact with several GPCRs, including
with the 3i loop of the D2 short and long isoforms of the
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the D4 or D1 3i loops.In cells lacking ABP-280 the abil-
ity of the D2 to inhibit forskolin-stimulated cAMP accu-
mulation is significantly reduced,although the receptor
affinities for agonists and antagonists were not altered.
46,47
It is interesting to notice that ABP-280 and spinophilin
bind to the same region (third intracellular loop of D2
receptors).However,no differences in ABP-280 expres-
sion were found in cortex from schizophrenic patients
compared with controls.
14
AKT/GSK3 pathway and dopaminergic signal
The human V-akt murine thymoma viral oncogene
homolog AKT1 and AKT2 genes are mammalian proto-
oncogenes of a viral oncogene known as V-AKT,related
to leukemia in mice.
48 Latter studies have found that the
proteins codified by these genes were related to protein
kinases A and C (PKA and PKC).
49-51 Named as PKB,
three family members with more than 80% homology
have been so far identified (AKT1/PKBα,AKT2/PKBβ
and AKT3/PKBγ).Disruption of the the serine/threonine
kinase (PKB/AKT) has been implicated in several
human cancers,and the enzyme seems to play an impor-
tant role in their outcome.
52 In 1995,it was demonstrated
that AKT/PKB was a direct effector of phosphatidyli-
nositol-3-OH kinase (PI-3 kinase).
53,54 Later in the same
year,Cross et al
55 showed that AKT/PKB phosphorylates
glycogen synthase kinase-3 (GSK3),being a key factor in
that signaling cascade,linking PI-3K to to basic metabolic
functions,such as protein and lipid synthesis,carbohy-
drate metabolism,and transcription.
52
AKT/PKB became interesting for psychiatry when it was
found that both isoforms of GSK-3 (α and β) are inhibited
by lithium (Li
+).
56,57This inhibition seems to be due to com-
petition for magnesium (Mg
2+) binding at a site distinct
from the ATP binding site
58,59 and occurs at expected ther-
apeutic concentrations of the drug used as a mood stabi-
lizer.The neuroprotectant effect of Li
+ seems to be due to
inhibition of GSK-3β that results in accumulation of the
antiapoptotic factor β-catenin,
60 which is also affected by
other mood stabilizers such as lamotrigine and valproate.
61
The first report of a possible involvement of GSK-3 in
schizophrenia was by Yang et al,
62 where they showed that
both cellular activities and protein levels of kinase
FA/GSK-3α in the lymphocytes of schizophrenic patients
were greatly impaired compared with normal controls.
More recently,low immunoreactivity and activity of GSK-
3β was demonstrated in the postmortem frontal cortex of
schizophrenic patients,
63-65 but at least one negative study
was also reported for a different brain collection,
66 which
made the authors stress the need to be cautious with
interepretation of data from postmortem samples.
In an elegant study,Emamian et al
67 have shown that lev-
els of AKT1,but not of AKT2 or AKT3,was reduced in
lymphocytes and in frontal cortex of schizophrenic patients
compared with controls.In contrast,the expression levels
of GSK-3β was not altered in patient's lymphocytes and
was slightly decreased in brain tissue.However,when the
AKT1-dependent phosphorylation levels of GSK-3β at
serine-9 was significantly lower in lymphocytes and frontal
cortex of schizophrenic patients. In addition, they have
shown that treatment of mice with haloperidol induced an
increase in phosphorylation of GSK-3β Ser-9.
Evidence of the involvement of the AKT/GSK-3β path-
way with dopamine-dependent behaviors and signaling
was recently shown.
68 The authors demonstrated that
increased dopaminergic neurotransmission in mice stria-
tum, resulted in inactivation of AKT and concomitant
activation of GSK-3α and GSK-3β,which was affected
by activation of the cAMP pathway,as shown by the lack
of phosphorylation changes in DARRP-32 Thr-34.
However,these effects were effectively reversed either
by inhibition of dopamine synthesis,dopamine D2 recep-
tor (D2) blockade,or administration of lithium salts.In
addition, it was also shown that pharmacological or
genetic inhibition of GSK-3 significantly reduces
dopamine-dependent locomotor behaviors.
68 Taken
together,their findings suggest that D2 is responsible for
the regulation of AKT by dopamine.
67,68 In a further
development,Beaulieu et al
69 were able to show that a β-
arrestin 2-mediated kinase/phosphatase scaffolding of
AKT and protein phosphatase-2A (PP2A) was respon-
sible for the regulation of AKT by DA receptors.
Conclusion
There are many putative crossover points between the
abovementioned proteins and their regulated pathways,
and only an extensive investigation of many of these
steps will allow better comprehension of cellular signal-
ing mechanisms.These could turn out to be therapeutic
targets in the treatment of serious mental illnesses such
as schizophrenia. ❏
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Las proteínas integradoras de la señal 
dopaminérgica intracelular y su relevancia
para la esquizofrenia
Las modificaciones de la función dopaminérgica se
pueden regular a través de interacciones entre los
receptores o entre los receptores de dopamina y
otras proteínas o con los elementos de las cascadas
señalizadoras efectoras. La complejidad de la seña-
lización dopaminérgica no se ha aclarado ni mucho
menos. Sin embargo, podría aportar la clave para
entender la fisiopatología de los trastornos neuro-
lógicos y psiquiátricos e identificar posibles objeti-
vos nuevos que permitieran el desarrollo de fárma-
cos más eficaces y selectivos. En este artículo se
revisan algunas de las pruebas actuales y se propo-
nen nuevas ideas, además de exponer las perspec-
tivas futuras.
Application à la schizophrénie du signal
intracellulaire dopaminergique intégrant 
les protéines
L’interaction récepteur-récepteur, l’interaction
d’autres protéines avec des récepteurs à la dopa-
mine et/ou des éléments de la cascade de signalisa-
tion en aval peuvent réguler les modifications de la
fonction dopaminergique. La complexité de la
signalisation dopaminergique est loin d’être com-
plètement élucidée. Elle pourrait cependant être la
clé de la compréhension de la physiopathologie des
troubles neurologiques et psychiatriques, ainsi que
de l’identification d’éventuelles nouvelles cibles et
du développement de médicaments plus efficaces
et sélectifs. Cet article fait la mise au point de
quelques preuves actuelles et des nouvelles idées
qui en découlent ainsi que des perspectives d’ave-
nir maintenant bien reconnues.
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